A CVS pharmacy recently sent me a standardized form by fax with a dire warning about one of my patients. The form was called “MEDICATION NONADHERENCE THERAPY ADVISORY” and it said: “A review of your patient’s retail and mail prescription history indicates that the patient has not obtained his or her first refill.”
Gabriel Ivbijaro and Lucja Kolkiewicz produce five pages dedicated to improving adherence with psychiatric medication through collaborative care and the implementation of modified CBT. The use of the word ‘collaborative’ in this context is misleading.
I believe now that fifteen years is more than a fair try. Fifteen years of getting treatment without returning to function is actually insanity. I should have given up after year two. Instead of trusting my intuition and insight, I pushed it down and down... until it finally fought its way back to the surface.
For weeks I had been trying to get released from the psychiatric ward, and none of my arguments, compliance, or attempted air of normality had made an impression on the barely-visible ward psychiatrist. I had, I was told, made a very serious suicide attempt and this was a predictor of future attempts. They would let me know when they thought I was sufficiently remorseful and stabilized to be released.
Last Thursday, the FDA agreed to review a “digital pill,” combining a sensor with the antipsychotic Abilify, in order to track patients’ compliance with drug treatment. Patients taking the tracker pill would also wear a patch, which would receive information and relay it to a mobile device, according to a brief report by BioPharmaDIVE.